Use of MDMA (Ecstasy) in Psychotherapy Sessions for the Treatment of Chronic PTSD: a bibliometric study

Authors

DOI:

https://doi.org/10.9771/cp.v18i1.60455

Keywords:

MDMA, PTSD, Psychotherapy.

Abstract

This article is a literature review regarding the clinical use of the substance 3,4-Methylenedioxymethamphetamine, also known as MDMA or Ecstasy, to assist in psychotherapy sessions in the treatment of post-traumatic stress disorder (PTSD). Due to the symptomatic characteristics, the disorder is commonly treated with antidepressants, which act on neurotransmitters in addition to psychotherapeutic monitoring. However, some patients do not adapt to the available treatment and the disorder becomes chronic. To search for articles, the PubMed and Scielo databases were used. To search for patents and their technologies, the Orbit Intelligence platform was used, using “MDMA” or “3,4-Methylenedioxyamphetamine” as keywords. The most recent articles demonstrate that MDMA is a potential substance to assist psychotherapy in the treatment of PTSD. Furthermore, the technologies most associated with MDMA innovations are present in patents, such as patent application “JP2023549405”, for an MDMA prodrugs.

Downloads

Download data is not yet available.

Author Biographies

Rachel Lais Brandão Viana, University of Brasília

Bachelor of Pharmacy from the University of Brasília in 2024.

Maria Hosana Conceição, University of Brasília

PhD in Chemistry from the University of Brasília in 2002.

References

APA – AMERICAN PSYCHIATRIC ASSOCIATION. DSM-5, Porto Alegre: Grupo A, 2016. (E-book). ISBN 9788582711835. Disponível em: https://integrada.minhabiblioteca.com.br/#/books/9788582711835/. Acesso em: 3 out. 2023.

BEAR, M. F. et al. Neurociências. Porto Alegre: Grupo A, 2017. (E-book). ISBN 9788582714331. Disponível em: https://integrada.minhabiblioteca.com.br/#/books/9788582714331/. Acesso em: 14 jan. 2024.

BERSHAD, A. K. et al. MDMA does not alter responses to the Trier Social Stress Test in humans. Publimed, [s.l.], v. 234, n. 14, p. 2.159-2.166, 2018.

DALGALARRONDO, P. Psicopatologia e semiologia dos transtornos mentais. Porto Alegre: Grupo A, 2019. (E-book). ISBN 9788582715062. Disponível em: https://integrada.minhabiblioteca.com.br/#/books/9788582715062/. Acesso em: 1º set. 2023.

DIEHL, A.; CORDEIRO, D. C.; LARANJEIRA, R. Tratamentos farmacológicos para dependência química. Porto Alegre: Grupo A, 2011. (E-book). ISBN 9788536322445. Disponível em: https://integrada.minhabiblioteca.com.br/#/books/9788536322445/. Acesso em: 1º set. 2023.

ECONOMIST, The. How MDMA is being used to treat PTSD. YouTube, 11 de out. de 2018. Disponível em: https://www.youtube.com/watch?v=8K5sJuTbQvY. Acesso em: 1º nov. 2023.

ELISABETSKY, E. et al. Descomplicando a psicofarmacologia. São Paulo: Editora Blucher, 2021. (E-book). ISBN 9786555062717. Disponível em: https://integrada.minhabiblioteca.com.br/#/books/9786555062717/. Acesso em: 1º set. 2023.

FORD, S. M. Farmacologia Clínica. Rio de Janeiro: Grupo GEN, 2019. (E-book). ISBN 9788527735681. Disponível em: https://integrada.minhabiblioteca.com.br/#/books/9788527735681/. Acesso em: 1º set. 2023.

INPI – INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL. Sobre o INPI. 2024. Disponível em: https://www.gov.br/inpi/pt-br. Acesso em: 2 abr. 2024.

MORGAN, L. MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: What it is and what it isn’t. Annals of General Psychiatry, [s.l.], v. 19, n. 1, p. 1-7, 2020.

MYDECINE INNOVATIONS GROUP. Short-acting psychoactive compounds from the MDMA class. US11896577. Depósito: 12 de junho de 2023.

OMPI – ORGANIZAÇÃO MUNDIAL DA PROPRIEDADE INTELECTUAL. O que é uma Patente? 2024. Disponível em: https://www.wipo.int/patents/en/. Acesso em: 2 abr. 2024.

ORBIT INTELLIGENCE. Página de busca. 2024. Disponível em: https://www.questel.com/patent/ip-intelligence-software/orbit-intelligence/. Acesso em: 12 jun. 2024.

PAREKH, S. V. et al. MDMA administration attenuates hippocampal IL-β immunoreactivity and subsequent stress-enhanced fear learning: An animal model of PTSD. Brain, Behavior, and Immunity – Health, [s.l.], v. 26, n. August, p. 100542, 2022.

PLUMMER, C. M. et al. The synthesis and characterisation of MDMA derived from a catalytic oxidation of material isolated from black pepper reveals potential route specific impurities. Science & Justice, [s.l.], v. 56, n. 3, p. 223-230, 2016.

RITTER, J. M. Rang & Dale Farmacologia. Rio de Janeiro: Grupo GEN, 2020. (E-book). ISBN 9788595157255. Disponível em: https://integrada.minhabiblioteca.com.br/#/books/9788595157255/. Acesso em: 20 jan. 2024.

WAGNER, M. T. et al. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. Journal of Psychopharmacology, [s.l.], v. 31, n. 8, p. 967-974, 2017.

YEDA RESEARCH & DEVELOPMENT. Compositions and methods for treating mdma-induced toxicity. US20050267050. Depósito: 12 de março de 2003.

ZEIFMAN, R. J. et al. Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder. European Journal of Psychotraumatology, [s.l.], v. 15, n. 1, p. 2297536, 2024.

Published

2025-01-01

How to Cite

Viana, R. L. B., & Conceição, M. H. (2025). Use of MDMA (Ecstasy) in Psychotherapy Sessions for the Treatment of Chronic PTSD: a bibliometric study. Cadernos De Prospecção, 18(1), 291–305. https://doi.org/10.9771/cp.v18i1.60455

Issue

Section

Prospecções Tecnológicas de Assuntos Específicos